Marker Therapeutics (MRKR) Change in Account Payables (2014 - 2026)
Marker Therapeutics (MRKR) posted quarterly Change in Account Payables of $1.0 million for Q1 2026, up 177.07% year-over-year from $361367.6 in Q1 2025, and up 404.96% quarter-over-quarter from -$328315.0 in Q4 2025.
Marker Therapeutics (MRKR) Change in Account Payables (2014 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Change in Account Payables for 7 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 177.07% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $589902.0 (up 928.38% YoY), while the FY2025 annual figure was -$1.7 million, down 549.13% from the prior year.
- Change in Account Payables grew to $1.0 million in Q1 2026 per MRKR's latest filing, from -$328315.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.0 million in Q1 2026 and bottomed at -$2.9 million in Q3 2022.
- Historically, Change in Account Payables has averaged -$566668.2 across 5 years, with a median of -$328315.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 499.54% in 2025 and fell as far as 153.75% in 2025.
- Marker Therapeutics' Change in Account Payables stood at -$2.6 million in 2022, then jumped by 137.72% to $961740.0 in 2023, then decreased by 16.08% to $807062.0 in 2024, then slumped by 140.68% to -$328315.0 in 2025, then jumped by 404.96% to $1.0 million in 2026.
- Business Quant data shows MRKR's Change in Account Payables at $1.0 million in Q1 2026, -$328315.0 in Q4 2025, and -$328316.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | -196,434.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | -328,315.00 |
| Dec 31, 2025 | -328,315.00 |
| Sep 30, 2025 | -328,316.00 |
| Sep 30, 2025 | -328,316.00 |
| Jun 30, 2025 | 245,304.00 |
| Jun 30, 2025 | 245,304.00 |
| Mar 31, 2025 | -1.30 Mn |
| Mar 31, 2025 | -1.30 Mn |
| Dec 31, 2024 | 807,062.00 |
| Dec 31, 2024 | 807,062.00 |
| Sep 30, 2024 | 610,869.00 |
| Sep 30, 2024 | 610,869.00 |
| Jun 30, 2024 | -61,396.00 |
| Jun 30, 2024 | -61,396.00 |
| Mar 31, 2024 | -975,690.00 |
| Mar 31, 2024 | -975,690.00 |
| Dec 31, 2023 | 961,740.00 |
| Dec 31, 2023 | 961,740.00 |